GBSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 10月 2022 @ 13:00):

Stats
本日の出来高	9 030
平均出来高	51 580
時価総額	433 577
EPS	$-2.07 ( Q2 \| 2024-02-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.943 (Sector) 42.63 (Industry) 43.86
ATR14	$0.0690 (14.58%)

ABMD 0.00%

AMIX -4.95%

BBLGW -21.85%

BVS 0.52%

COCH 3.06%

DHAI -3.26%

DHAIW -22.93%

DNAY 8.33%

EYES -5.05%

GBS -1.58%

HSCS -1.70%

HSCSW -32.26%

IINNW 1.61%

INVO -3.33%

LFWD 1.26%

MDAI -2.22%

MGRM 3.86%

MXCT -2.00%

NVNOW -32.98%

NXL -42.91%

NXLIW -15.00%

OSA -7.35%

OSAAW -6.40%

PAVMW 105.67%

PAVMZ 0.00%

PETVW 0.00%

QTI 2.21%

QTNT 0.00%

Insider Trading

Date	Person	Action	Amount	type
2023-10-04	Sakiris Spiro Kevin	Buy	0
2023-10-04	Towers Christopher	Buy	9 090	Common Stock
2023-10-04	Towers Christopher	Buy	9 090	Common Stock Warrants (Series E)
2023-10-04	Towers Christopher	Buy	9 090	Common Stock Warrants (Series F)
2023-10-04	Sakiris Spiro Kevin	Buy	112 727	Common Stock

INSIDER POWER
95.36
Last 80 transactions
Buy: 892 204 \| Sell: 7 603 867

ボリューム相関

長: 0.00 (neutral)

短: -0.11 (neutral)

Signal:(47.602) Neutral

GBS Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

GBS Inc. 相関 - 通貨/商品

0.48
( neutral )

-0.49
( neutral )

0.00
( neutral )

0.45
( neutral )

0.55
( weak )

-0.39
( neutral )

GBS Inc. 財務諸表

Annual	2023
収益:	$1.26M
総利益:	$326 668 (25.99 %)
EPS:	$-10.58

FY	2023
収益:	$1.26M
総利益:	$326 668 (25.99 %)
EPS:	$-10.58

FY	2022
収益:	$437 146
総利益:	$437 146 (100.00 %)
EPS:	$-0.570

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.625

Financial Reports:

No articles found.

GBS Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

GBS Inc.

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.